-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $110

Benzinga·11/06/2026 14:39:12
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $95 to $110.